This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

This study has been completed.
Information provided by (Responsible Party):
Warner Chilcott Identifier:
First received: February 3, 2009
Last updated: June 3, 2013
Last verified: June 2013
This study analysed and reported on the study data from three similar, risedronate studies, 1996052, 2003073, and 2003096. The objective of the study was to determine the differences in the iliac crest bone histomorphometry and bone quality in postmenopausal women who had received long term therapy with risedronate.

Condition Intervention Phase
Osteoporosis Drug: risedronate Phase 4

Study Type: Observational
Official Title: Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Risedronate Daily or Weekly

Resource links provided by NLM:

Further study details as provided by Warner Chilcott:

Primary Outcome Measures:
  • Differences in iliac crest bone histomorphometry and bone quality in patients receiving risedronate [ Time Frame: 5 years ]

Enrollment: 29
Study Start Date: April 2003
Study Completion Date: October 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Women taking risedronate for 5 years
Drug: risedronate
risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed month 36 of Study RVN-008993.
  • Underwent an iliac crest bone biopsy at month 36.

Exclusion Criteria:

  • Was less than 60% compliant with regard to taking study drug from the start of the study drug to month 24 of study RVN-008993.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00837746

United States, California
Maria Greenwald, MD
Palm Desert, California, United States, 92260
United States, Colorado
Paul Miller, MD
Lakewood, Colorado, United States, 80227
United States, Georgia
Grattan Woodson, MD
Decatur, Georgia, United States, 30033
Christopher Recknor, MD
Gainesville, Georgia, United States, 30501
United States, Nebraska
Robert Recker, MD
Omaha, Nebraska, United States, 68131
United States, Ohio
Nelson Watts, MD
Cincinnati, Ohio, United States, 45219
United States, Pennsylvania
Ronald D Emkey, MD
Wyomissing, Pennsylvania, United States, 19610
Canada, Quebec
Louis-Georges Ste-Marie, MD
Montreal, Quebec, Canada, H2X 1P1
Sponsors and Collaborators
Warner Chilcott
Study Director: Ana M Balske, MD Procter and Gamble
  More Information

Responsible Party: Warner Chilcott Identifier: NCT00837746     History of Changes
Other Study ID Numbers: 2004140
Study First Received: February 3, 2009
Last Updated: June 3, 2013

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Risedronate Sodium
Etidronic Acid
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on August 17, 2017